...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
AGORACOM NEWS FLASH

Dear Agoracom Family,

I want to thank all of you for your patience with us over the past 48 hours and apologize for what was admittedly a botched launch of our new site.

As you can see, we have reverted back to the previous version of the site while we address multiple forum functionality flaws that inexplicably made their way into the launch.

To this end:

1.We have identified 8 fundamental but easily fixable flaws that will be corrected in the coming week, so that you can continue to use the forums exactly as you've been accustomed to.

2.Additionally we will also be implementing a couple of design improvements to "tighten up" the look and feel of the forums.

Sincerely,

George et al

Message: My email and response re eGFR data...
Reply New Message
Prev Message Back To Forum Threaded View Next Message

Busy day at IR,... my response just received:

Following our Sept 30 NR, where we reported that BETonMACE did not meet its primary endpoint, all preliminary analysis of key secondary and exploratory endpoints, including cognitive decline in this patient population, were reported in the same manner – conference call and webcast. Any decisions on Company NRs are made at the senior management level. Both AHA and CtAD conferences had media presence and the Company took advantage of all interview opportunities when embargos were lifted.

 

The Nov. 18 and Dec. 6 webcast / conf. call and presentations have all the updated info as to next commercialization steps and the information has been widely shared to the general public and beyond.

3 Recommendations
Reply New Message
Prev Message Back To Forum Threaded View Next Message
Share
Share
New Message
Please login to post a reply